PMID- 34120744
OWN - NLM
STAT- MEDLINE
DCOM- 20220309
LR  - 20220309
IS  - 1465-3931 (Electronic)
IS  - 0031-3025 (Linking)
VI  - 53
IP  - 7
DP  - 2021 Dec
TI  - Evaluation of the BioFire Blood Culture Identification 2 panel and impact on 
      patient management and antimicrobial stewardship.
PG  - 889-895
LID - S0031-3025(21)00133-1 [pii]
LID - 10.1016/j.pathol.2021.02.016 [doi]
AB  - Bloodstream infection survival is linked to timely administration of optimal 
      antimicrobial therapy. Commercial multiplex polymerase chain reaction (PCR) 
      assays, such as the BioFire Blood Culture Identification Panel (BCID) used for 
      the rapid diagnosis of bloodstream infections, have significantly improved the 
      turnaround time for optimisation of antimicrobial therapy. Reported concordance 
      with culture-based methods and multiplex PCR analysis is high and only limited by 
      (1) the range of targets available on the multiplex panel; and (2) the complexity 
      of microorganisms present in the blood culture specimen. In this study, we 
      evaluated the use of the BioFire Blood Culture Identification 2 panel (BCID2), 
      including an expanded repertoire of targets for Gram-positive and Gram-negative 
      bacteria, yeast and antimicrobial resistance genes compared to the BCID panel. 
      The BCID2 panel identified microorganisms in 39/42 (92.9%) blood cultures where 
      monomicrobial growth was detected; the three unidentified blood cultures 
      contained organisms not included in the BCID2 panel. Polymicrobial blood culture 
      analysis revealed a lower degree of concordance (28.6%); however, most 
      disagreement was due to the culture-based identification of off-panel 
      microorganisms of low clinical significance. Turnaround time, from blood culture 
      collection to organism identification on the blood cultures correctly identified 
      by BCID2, was 24.6 (+/-16.8) hours for the BCID2 panel versus 38.2 (+/-21.9) hours 
      for conventional methods. Analysis of the theoretical impact of the BCID2 
      identification on clinical management found therapy would be altered in 45.1% 
      (23/51) of patients. The BCID2 panel is anticipated to improve the diagnosis and 
      antimicrobial management of patients with serious bloodstream infections.
CI  - Copyright (c) 2021 Royal College of Pathologists of Australasia. Published by 
      Elsevier B.V. All rights reserved.
FAU - Sparks, Rebecca
AU  - Sparks R
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Blue Mountains Pathology Service, Penrith, NSW, Australia.
FAU - Balgahom, Rifky
AU  - Balgahom R
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Blue Mountains Pathology Service, Penrith, NSW, Australia.
FAU - Janto, Catherine
AU  - Janto C
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Blue Mountains Pathology Service, Penrith, NSW, Australia.
FAU - Polkinghorne, Adam
AU  - Polkinghorne A
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Blue Mountains Pathology Service, Penrith, NSW, Australia; Nepean Clinical 
      School, Faculty of Medicine and Health, University of Sydney, Kingswood, NSW, 
      Australia.
FAU - Branley, James
AU  - Branley J
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Blue Mountains Pathology Service, Penrith, NSW, Australia; Nepean Clinical 
      School, Faculty of Medicine and Health, University of Sydney, Kingswood, NSW, 
      Australia. Electronic address: james.branley@health.nsw.gov.au.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20210611
PL  - England
TA  - Pathology
JT  - Pathology
JID - 0175411
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Anti-Infective Agents/*pharmacology/therapeutic use
MH  - Antimicrobial Stewardship
MH  - Australia
MH  - Blood Culture
MH  - Drug Resistance, Microbial/genetics
MH  - Gram-Negative Bacteria/genetics/*isolation & purification
MH  - Gram-Positive Bacteria/genetics/*isolation & purification
MH  - Humans
MH  - Multiplex Polymerase Chain Reaction
MH  - Sepsis/*diagnosis/drug therapy/microbiology
MH  - Yeasts/genetics/*isolation & purification
OTO - NOTNLM
OT  - Bloodstream
OT  - PCR
OT  - antimicrobial resistance
OT  - blood culture
EDAT- 2021/06/15 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/06/14 06:13
PHST- 2020/10/26 00:00 [received]
PHST- 2021/02/10 00:00 [revised]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/06/14 06:13 [entrez]
AID - S0031-3025(21)00133-1 [pii]
AID - 10.1016/j.pathol.2021.02.016 [doi]
PST - ppublish
SO  - Pathology. 2021 Dec;53(7):889-895. doi: 10.1016/j.pathol.2021.02.016. Epub 2021 
      Jun 11.